Spondyloarthritis & psoriatic arthritis
The evolving demographics of participants in psoriatic arthritis phase III randomised controlled trials of b/tsDMARDs: A systematic review
Authors' conclusion
Despite the expansion of countries from which PsA RCT participants were recruited from, non-white participants continue to be under-represented.
Study context
- Population
- Participants in placebo-controlled phase III randomised controlled trials (RCTs) of b/tsDMARDs in peripheral psoriatic arthritis (PsA) published up to 1 June 202234 RCTs from 33 reports
- Comparison
- 2000-2004 vs 2015-2019
- Outcome
- Evolving demographics of participants (sex, race, countries, disease activity) over time
Methodological detailsplacebo-controlled phase III RCTs, descriptive statistics
- Placebo-controlled phase III RCTs
- Descriptive statistics
Pooled result
As reported in the abstract
Participant demographics by trial initiation period
- Female participants, 2000-2004
- 29.0-43.7%
- Female participants, 2015-2019
- 46.0-58.8%
- Number of countries, 2000-2004
- 1-8
- Number of countries, 2015-2019
- 2-46
- White participants, 2000-2004
- 90.0-98.0%
- White participants, 2015-2019
- 80.9-97.3%
- SJC and TJC, 2000-2004
- 13.9 to 24.6
- SJC, 2015-2019
- 7.0-13.9
- TJC, 2015-2019
- 12.9-24.9
Original publication
The evolving demographics of participants in psoriatic arthritis phase III randomised controlled trials of b/tsDMARDs: A systematic review. Semin Arthritis Rheum. Published 14 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →